Presentations

We reported final 24-month results from the subgroup of hereditary ATTR (hATTR) amyloidosis patients with cardiac involvement in the Phase 2 open-label extension (OLE) study of patisiran at the European Society of Cardiology Heart Failure (ESC-HF) Congress in Paris, France. [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ESC-HF-2017_P2-OLE-Cardiac_04292017.pdf" type="(432 KB PDF)"]View the presentation[/spotlight-link]

We reported final 24-month results from our Phase 2 open-label extension (OLE) study of patisiran, an investigational RNAi therapeutic targeting transthyretin (TTR) for the treatment of hereditary ATTR (hATTR) amyloidosis. These data were presented at the American Academy of Neurology (AAN) 2017 Annual Meeting in Boston, Massachusetts. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1022960" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/AAN-2017_Patisiran_Ph-2-OLE_Final-24mos_042617.pdf" type="(940 KB PDF)"]View the presentation[/spotlight-link]

We presented results from a survey evaluating the utility and user experience of an independent genetic testing and counseling service for hereditary ATTR (hATTR) amyloidosis that is supported by Alnylam – Alnylam Act – at the American College of Medical Genetics and Genomics (ACMG) Annual...

Alnylam and The Medicines Company reported final results from the ORION-1 Phase 2 study of inclisiran, an investigational RNAi therapeutic targeting PCSK9 for the treatment of hypercholesterolemia, at the American College of Cardiology (ACC) Scientific Session 2017 in Washington DC. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1017881" type=" "]Read the press release[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ACC_Ray-401-18_ORION-1_031717.pdf" type="(380 KB PDF)"]View the presentation[/spotlight-link]

We reported new results from an exploratory analysis of our Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia A or B with or without inhibitors at the 10th Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD) held February 1 – 3, 2017 in Paris, France. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1010213" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/EAHAD-2017_Management-of-Bleed-Events.pdf" type="(450 KB PDF)"]View the bleed management presentation[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/EAHAD-2017_Stability.pdf" type="(690 KB PDF)"]View the stability study presentation[/spotlight-link]

On December 16, 2016, we hosted our fourth consecutive R&D Day in New York City. Alnylam management and key opinion leaders discussed our most advanced clinical programs, reviewing all the latest data for patisiran, fitusiran and givosiran. [spotlight-link icon="podcast" href="https://event.webcasts.com/starthere.jsp?ei=1128976" type=""] Access the replay[/spotlight-link][spotlight-link icon="presentation" href=" http://216.92.19.121/rdday2016/#presentations" type=""]...

We reported new results from Part C of our Phase 1/2 clinical study of ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases, at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002720" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ASH-2016_CC5_Ph-1-Part-C_05Dec2016_CAPELLA.pdf" type="(730 KB PDF)"]View the presentation[/spotlight-link]

We reported positive interim results from our Phase 1 study of fitusiran in patients with hemophilia with inhibitors as well as from our Phase 2 open-label extension (OLE) study in hemophilia patients without inhibitors at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002502" type=" "]Read our press release on hemophilia patients with inhibitors[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ASH-2016_Fitusiran_INHIBITORS_03Dec2016_CAPELLA.pdf" type="(320 KB PDF)"]View the inhibitor presentation[/spotlight-link] [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002510" type=" "]Read our press release on fitusiran Phase 2 OLE [/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ASH-2016_Fitusiran_NONINHIBITORS_04Dec2016_CAPELLA2.pdf" type="(460 KB PDF)"]View the Phase 2 OLE presentation[/spotlight-link]

We reported positive initial results from Cohorts 1 and 2 in Part C of our Phase 1 study with givosiran (gi-VOH-si-ran), the International Nonproprietary Name for ALN-AS1, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias.  These results were presented at the 58th Annual Meeting of the American Society of Hematology (ASH), held December 3 – 6, 2016 in San Diego, California. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1002501" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ASH-2016_Givosiran_Ph-1-Part-C_03Dec2016_CAPELLA.pdf" type="(470 KB PDF)"]View the presentation[/spotlight-link]

SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.